Steve Soper,
Foundation Distinguished Professor, Director, Center of BioModular Multi-Scale System for Precision Medicine,
The University of Kansas
Prof. Soper is currently a Foundation Distinguished Professor in Chemistry and Mechanical Engineering at the University of Kansas, Lawrence. Prof. Soper also holds an appointment at Ulsan National Institute of Science and Technology in Ulsan, South Korea, where he is a World Class University Professor. He is also serving as a Science Advisor for a number of major worldwide companies. Prof. Soper is currently on the Editorial Board for Scientific Reports and Journal of Micro- and Nanosystems.
As a result of his efforts, Prof. Soper has secured extramural funding totaling >$103M and has published over 265 peer-reviewed manuscripts (h index = 71) and is the author of 20 patents. He is also the founder of a startup company, BioFluidica, which is marketing devices for the isolation and enumeration of circulating tumor cells. His list of awards includes Chemical Instrumentation by the American Chemical Society, the Benedetti-Pichler Award for Microchemistry, Fellow of the AAAS, Fellow of Applied Spectroscopy, Fellow of the Royal Society of Chemistry, R&D 100 Award, Distinguished Masters Award at LSU and Outstanding Scientist/Engineer in the state of Louisiana in 2001. Finally, Prof. Soper has granted 60 PhDs and 6 MS degrees to students under his mentorship. He currently heads a group of 20 researchers.
New Tools for Liquid Biopsies: Microfluidic Platforms for the Efficient Isolation and Molecular Profiling of Circulating Tumor Cells (CTCs), Cell Free DNA (cfDNA) and Nanovesicles (Exosomes)
Monday, 20 March 2017 at 11:15
Add to Calendar ▼2017-03-20 11:15:002017-03-20 12:15:00Europe/LondonNew Tools for Liquid Biopsies: Microfluidic Platforms for the Efficient Isolation and Molecular Profiling of Circulating Tumor Cells (CTCs), Cell Free DNA (cfDNA) and Nanovesicles (Exosomes)SELECTBIOenquiries@selectbiosciences.com
Liquid biopsies are generating great interest within the biomedical
community due to the simplicity for securing important biomarkers to
manage complex diseases, such as many of the cancer-related diseases.
These circulating markers consist of CTCs, cfDNA and exosomes. We are
developing a suite of microfluidic devices that are can process whole
blood directly and engineered to efficiently search for a variety of
disease-associated liquid biopsy markers from divergent subpopulations
comprising the tumor microenvironment that can supply complementary
clinical information. Each microfluidic device can isolate the target
with recovery >90% and sufficient purity (>80%) to enable
downstream molecular analysis of the particular biomarker. The
microfluidic devices are made from thermoplastics via injection molding
to allow for mass-production of devices with tight compliancy to
accommodate clinical implementation. In this presentation, information
will be shared on the operational parameters of these devices for the
selection of liquid biopsy markers, and the downstream molecular
information that can be garnered from the isolated markers in diseases
such as colorectal, ovarian, breast, pancreatic and prostate cancers as
well as some of the liquid-based cancers (acute myeloid leukemia).
Add to Calendar ▼2017-03-20 00:00:002017-03-21 00:00:00Europe/LondonExosomes and Extracellular Vesicles (EV): Research, Diagnostics and Therapeutics OpportunitiesSELECTBIOenquiries@selectbiosciences.com